Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Biotech
Pfizer offloads scrapped Seagen ADC to Medicus Pharma
Medicus paying $12 million upfront for rights to PF-08046031, which is designed to attack a cancer target called melanotransferrin or CD228.
Darren Incorvaia
Sep 3, 2026 11:31am
Genentech doubles down on ADC-resistance via $1B DualityBio pact
Aug 28, 2026 4:30am
Pathos AI pads pipeline with $2.2B Alphamab deal, AZ pact
Aug 4, 2026 7:36am
BMS CEO doesn’t ‘feel any compulsion to chase deals’
Jul 30, 2026 10:37am
Merck briefly posts trial plan for PD-1xVEGF and TROP2 ADC combo
Jul 29, 2026 3:00pm
GSK partner Hansoh reports another phase 3 win for priority ADC
Jul 28, 2026 8:20am
